TRAX · Categories · Coverage
TRAX - Analyst coverage initiated
First Tracks Biotherapeutics Inc. (TRAX) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for TRAX
- Canaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price targetCanaccord Genuity initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $50.00
- Evercore ISI initiated coverage on First Tracks Biotherapeutics with a new price targetEvercore ISI initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $65.00
- Guggenheim initiated coverage on First Tracks Biotherapeutics with a new price targetGuggenheim initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $100.00
- Wolfe Research initiated coverage on First Tracks Biotherapeutics with a new price targetWolfe Research initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $83.00
- Wells Fargo initiated coverage on First Tracks Biotherapeutics with a new price targetWells Fargo initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $30.00
- Piper Sandler initiated coverage on First Tracks Biotherapeutics with a new price targetPiper Sandler initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $54.00
- H.C. Wainwright initiated coverage on First Tracks Biotherapeutics with a new price targetH.C. Wainwright initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $30.00
- Wedbush initiated coverage on First Tracks Biotherapeutics with a new price targetWedbush initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $30.00
- Leerink Partners initiated coverage on First Tracks Biotherapeutics with a new price targetLeerink Partners initiated coverage of First Tracks Biotherapeutics with a rating of Outperform and set a new price target of $46.00
- Analyst initiated coverage on First Tracks Biotherapeutics with a new price targetAnalyst initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $31.00
- Barclays initiated coverage on First Tracks Biotherapeutics with a new price targetBarclays initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $40.00
- UBS initiated coverage on First Tracks Biotherapeutics with a new price targetUBS initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $45.00